Company Overview and News

 
Citi initiates coverage on HDFC Asset Management

2018-09-12 thehindubusinessline
Citi has initiated coverage on HDFC Asset Management Co (HDFC AMC) with “neutral” rating and a price target of Rs 1,850, saying it's a leader in an underpenetrated market.
HDFCNIFETF 539516

 
NTPC’s silence on stressed power plants must be appreciated

2018-09-10 livemint
Writing for Mint last year, Prashant Jain, executive director and chief investment officer of HDFC Mutual Fund, said it was not easy to remain invested in equities for long periods. “Those who can simply sit still know its immense benefits,” wrote Jain. NTPC Ltd seems to be practising this precept, albeit in a slightly different way.
HDFCNIFETF 539516 NTPZY

 
I-Sec row: ICICI Prudential books ₹97-crore loss, repays investors

2018-08-28 thehindubusinessline
Suresh P Iyengar To comply with market regulator SEBI’s direction, ICICI Prudential Mutual Fund has booked a loss of ₹97 crore by selling 4.61 million shares of ICICI Securities (I-Sec) stocks below its IPO subscription price of ₹520 a share and repaid investors with 15 per cent interest last Friday.
HDFCNIFETF 539516

 
Bombay High Court to decide on Leo Puri’s extension on Monday

2018-08-09 livemint
Mumbai: The Bombay High Court will, on Monday, give its verdict on the extension of the tenure of Leo Puri, managing director, UTI Asset Management Company. Global asset management company T. Rowe Price had filed a writ petition in court with the argument that any move to remove the managing director would have an adverse impact on the fund house, which was preparing for its maiden initial public offering.
HDFCNIFETF PNJZY 532461 PNB 539516 SBAZ

 
SEBI writes to AMFI, mutual funds against 25 violations

2018-07-26 moneycontrol
The capital market regulator has written a letter to the chief executive officers of asset management companies against 25 violations by the mutual fund industry.
HDFCNIFETF 539516

 
HDFC Mutual Fund seeks SEBI nod to launch low volatility ETF

2018-07-24 moneycontrol
HDFC Mutual Fund has sought Securities and Exchange Board of India's approval to launch HDFC Low Volatility ETF, according to the draft offer document filed on the regulator's website.
HDFCNIFETF 539516

 
7 cos to tap capital market to raise Rs 14,000 cr

2018-07-19 freepressjournal.in
New Delhi : The IPO lane is getting busy as at least seven companies, including Lodha Developers and HDFC Mutual Fund, are expected to hit the capital market in the coming week to raise over Rs 14,000 crore.
HDFCNIFETF 539516

 
‘Deploying equity inflows is not an issue’

2018-07-18 thehindubusinessline
18/07/2018 MUMBAI: Milind Barve, MD, HDFC Asset Management Company Ltd at a press conference to announce the company's Initial Public Offer in Mumbai on July 18, 2018. Photo: Paul Noronha - PAUL NORONHA
HDFCNIFETF 539516

 
HDFC MF’s public float to open on July 25 @₹1,095-1,100 a share

2018-07-17 thehindubusinessline
HDFC Mutual Fund has fixed the priced band for its initial public offering at ₹1,095-1,100 an equity share with a minimum bid lot size of 13 equity shares and in multiples of 13 equity shares thereafter.
HDFCNIFETF 539516

 
7 cos to tap capital market to raise Rs 14,000 cr

2018-07-16 freepressjournal.in
New Delhi : The IPO lane is getting busy as at least seven companies, including Lodha Developers and HDFC Mutual Fund, are expected to hit the capital market in the coming week to raise over Rs 14,000 crore.
HDFCNIFETF 539516

 
Dalal Street ready for Rs 14,000-cr IPOs

2018-07-15 thehindubusinessline
The IPO lane is getting busy as at least seven companies, including Lodha Developers and HDFC Mutual Fund, are expected to hit the capital market in the coming weeks to raise over Rs 14,000 crore. The first among the lot would be TCNS Clothing, which sells its products under W, Aurelia and Wishful brands, that will launch its Rs 1,125-crore initial share-sale this week.
HDFCNIFETF SLFPF SL 539516 SLFPY

1
HDFC Group’s market cap crosses ₹ 10 trillion, Tata Group at ₹ 11 trillion

2018-07-10 livemint
New Delhi: Deepak Parekh-led financial services conglomerate HDFC Group on Tuesday saw the market capitalisation of its listed firms cross the ₹ 10 trillion mark, making it only the second Indian business house after the Tata group to achieve this feat. HDFC Group has four listed companies—Housing Finance Development Corp. Ltd, HDFC Bank Ltd, life insurance firm HDFC Standard Life Ltd and Gruh Finance Ltd.
GRUH HDFCNIFETF 532540 HDB 500180 GRHFY HDFCBANK TCS TTNQY 539516 511288

 
Are big mutual fund houses losing steam?

2018-07-09 thehindubusinessline
Suresh P Iyengar After receiving record investments over the past few years, mutual funds finally seem to be losing steam, with almost all top fund houses recording single digit growth or marginal fall in average assets under management (AUM) in the June quarter.
HDFCNIFETF 539516

 
Fund-raising via IPOs almost doubles to Rs 23,670 crore in H1 2018

2018-07-08 moneycontrol
In a blockbuster performance, as many as 18 companies have raised a staggering Rs 23,670 crore through initial public offerings in the first half of this year, almost double from the year-ago period.
HDFCNIFETF 539516

 
This week in Mutual Funds: Domestic MF#39;s AUM skewed to top 20 fund houses?

2018-07-07 moneycontrol
The average assets under management in Apr-Jun quarter of the 43-player mutual fund industry surged 20 percent from a year-ago to Rs 23.40 lakh crore, according to the data on the Association of Mutual Funds in India.
HDFCNIFETF 539516

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...